바이러스 벡터 생산 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Viral Vector Production Market size is expected to reach USD 13.28 Billion in 2034 from USD 2.76 Billion (2025) growing at a CAGR of 19.06% during 2026-2034.

The Global Viral Vector Production Market is witnessing rapid expansion driven by the surge in gene therapy, cell therapy, and vaccine development programs. Viral vectors are critical components in delivering genetic material into cells, making them indispensable in advanced biopharmaceutical research. Increasing clinical trials and regulatory approvals for gene-based therapies are significantly boosting production demand.

Growth drivers include technological advancements in vector engineering, improved scalability of manufacturing processes, and strong investments from pharmaceutical companies. The rising prevalence of rare genetic disorders and cancer further supports market expansion. Additionally, government funding and strategic collaborations between biotech firms and contract development organizations enhance production capacity worldwide.

Looking ahead, the market is expected to grow at an accelerated pace as personalized medicine gains mainstream acceptance. Automation, modular manufacturing facilities, and innovations in upstream and downstream processing will improve efficiency and reduce costs. As regulatory frameworks evolve to support advanced therapies, viral vector production will remain a cornerstone of next-generation biopharmaceutical development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

• Cancer
• Genetic Disorders
• Infectious Diseases
• Other Diseases

By Application

• Gene Therapy
• Vaccinology

By Viral Vector Type

• Adenoviral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Adeno-Associated Viral Vectors
• Other Viral Vectors

COMPANIES PROFILED

• Oxford Biomedica, Andelyn Biosciences, Thermo Fisher Scientific Inc, Danaher Corporation, Charles River Laboratories, FinVector Oy, TAKARA HOLDINGS INC, Lonza, Avid Bioservices Inc, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY VIRAL VECTOR TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Viral Vector Type
• 6.2. Adenoviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Lentiviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Retroviral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Adeno-Associated Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR PRODUCTION MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Indication
  • 7.2.2 By Application
  • 7.2.3 By Viral Vector Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Indication
  • 7.3.2 By Application
  • 7.3.3 By Viral Vector Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Indication
  • 7.4.2 By Application
  • 7.4.3 By Viral Vector Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Indication
  • 7.5.2 By Application
  • 7.5.3 By Viral Vector Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Indication
  • 7.6.2 By Application
  • 7.6.3 By Viral Vector Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL VIRAL VECTOR PRODUCTION INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Oxford Biomedica
  • 9.2.2 Andelyn Biosciences
  • 9.2.3 Thermo Fisher Scientific Inc
  • 9.2.4 Danaher Corporation
  • 9.2.5 Charles River Laboratories
  • 9.2.6 FinVector Oy
  • 9.2.7 TAKARA HOLDINGS INC
  • 9.2.8 Lonza
  • 9.2.9 Avid Bioservices Inc
  • 9.2.10 Novartis AG